Company: CI
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001739940-25-000037
Chunk: 130

Company: Cigna Group
Filing Date: 2025-10-30
Form: 10-Q
Item: Part II, Item 7
Chunk 130
---
 no outstanding balance under the Credit Agreement.In April 2025, the Company replaced its previous revolving credit agreements and entered into a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional one-year periods, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to $6.5 billion under the Credit Agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.The Credit Agreement includes an option to increase commitments up to $1.5 billion for a maximum total commitment of $8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of September 30, 2025.

Debt Covenants. The Company was in compliance with its debt covenants as of September 30, 2025.

Interest Expense. Interest expense on long-term and short-term debt was $363 million for the three months ended and $1.1 billion for the nine months ended September 30, 2025, compared with $380 million for the three months ended and $1.1 billion for the nine months ended September 30, 2024.

14

Note 8 – Common and Preferred Stock

DividendsThe following table provides details of the Company's dividend payments:Record DatePayment DateAmount per ShareTotal Amount Paid (in millions)2025March 5, 2025March 20, 2025$1.51$412June 3, 2025June 18, 2025$1.51